Related Experiment Videos
[Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study]
J T Andersen1, H Wolf, P Ekman
1Hvidovre Hospital, urologisk afdeling.
Ugeskrift for Laeger
|September 2, 1996
Summary
Finasteride treatment significantly improved symptoms and urinary flow in men with benign prostatic hyperplasia (BPH) over 24 months. The medication reduced prostate volume, halting disease progression compared to placebo.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- Symptomatic BPH can significantly impact quality of life.
Purpose of the Study:
- To evaluate the efficacy and safety of finasteride 5 mg daily for 24 months in men with moderately symptomatic BPH.
- To assess the impact of finasteride on urinary symptoms, urinary flow rate, and prostate volume.
Main Methods:
- Multicentre, double-blind, placebo-controlled study.
- Involved 707 patients with moderately symptomatic BPH.
- Efficacy assessed via validated symptom scores, maximum urinary flow rate, and prostate volume changes.
Main Results:
- Finasteride significantly improved symptom scores compared to placebo (p < 0.01).
- Maximum urinary flow rate increased by 1.8 ml/s in the finasteride group (p < 0.01).
- Prostate volume decreased by 19% with finasteride, while placebo group showed a 12% increase (p < 0.01).
- Finasteride was well-tolerated, and placebo patients experienced symptom progression.
Conclusions:
- Finasteride 5 mg daily effectively halts the progression of moderately symptomatic BPH over 24 months.
- The treatment demonstrates significant improvements in urinary symptoms and flow rates.
- Finasteride is a safe and well-tolerated option for managing BPH.